Navigation Links
Thoratec Announces Appointment of Paul LaViolette to Board of Directors
Date:5/15/2009

PLEASANTON, Calif., May 15 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced the election of Paul A. LaViolette, the former chief operating officer of Boston Scientific, to its board of directors. LaViolette was elected by the company's shareholders at the company's annual shareholders' meeting on May 13 and brings the number of the company's directors to eight.

LaViolette spent 14 years at Boston Scientific and served as chief operating officer from 2004-2008. Before that, he was senior vice president and group president for several of the company's divisions and its international operations. He was formerly associated with C.R. Bard, Inc., where he held senior management positions and led several of the company's divisions.

"We are pleased to have someone with Paul's broad cardiovascular and medical device experience joining our board. His industry knowledge and successful track record of growing medical technology businesses will be of great value to Thoratec as we pursue our growth strategies," said Gary F. Burbach, president and chief executive officer of Thoratec.

"I also want to acknowledge the contributions of those directors who are stepping down. Dr. J. Donald Hill, a founder of the company and a director since its inception, is a pioneer in the development and use of ventricular assist devices and played a major role at Thoratec throughout the history of the company. Howard Chase, who served as a director for more than 20 years, provided great counsel and support as the company became a leader in treating advanced stage heart failure," Burbach added.

Thoratec Corporation is a world leader in therapies to address advanced-stage heart failure. The company's product lines include the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System), with more than 13,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) division is a leader in point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web sites at http://www.thoratec.com or http://www.itcmed.com.

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation. ITC, A-VOX Systems AVOXimeter, HEMOCHRON, ProTime and IRMA are registered trademarks of International Technidyne Corporation. CentriMag is a registered trademark of Levitronix, LLC.

Many of the preceding paragraphs, particularly but not exclusively those addressing future performance, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "views," "expects," "plans," "hopes," "could," "will," and other similar words. Actual results, events or performance could differ materially from these forward-looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties, including risks related to regulatory approvals, the development of new markets including Destination Therapy, the growth of existing markets for our products, customer and physician acceptance of Thoratec products, changes in the mix of existing markets for our products, the results of enrollment in and timing of clinical trials, including the HeartMate II, the effects of FDA regulatory requirements and the effects of healthcare reimbursement and coverage policies. Forward-looking statements contained in this press release should be considered in light of these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading "Risk Factors" in Thoratec's most recent annual report on Form 10-K and as may be updated in subsequent SEC filings. These forward-looking statements speak only as the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Thoratec Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Thoratec Schedules Third Quarter Conference Call, Webcast
2. Thoratecs ITC Division Receives FDA Warning Letter
3. URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device
4. Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation
5. Thoratec Schedules First Quarter 2008 Conference Call, Webcast
6. Thoratec Schedules Second Quarter 2008 Conference Call, Webcast
7. Thoratec Reports 44 Percent Increase in Second Quarter Revenues;
8. Thoratec Presentation at Piper Jaffary Conference to be Webcast
9. Thoratec Schedules Fiscal 2008 Year-End Conference Call, Webcast
10. Thoratec Reports 34 Percent Increase in 2008 Revenues
11. Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million;
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 23, 2017 , ... "ProRandom is a set of camera tools that allow video editors to ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , With ... with video footage. ProRandom works by using a virtual camera to create the illusion ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... (OREF), in partnership with the American Society of Anesthesiologists® (ASA®), the Foundation ... the American Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... “The Inn at the Mill”: a ... unexpected fears in her quest to become happy and content. , “The Inn at ... Pennsylvania, has also lived in Germany and Vermont and is now living in Berks County ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities ... These resources have been developed for use by nutrition educators and influencers ...
(Date:1/23/2017)... , ... January 23, 2017 , ... “Some Infallible Characteristics ... the Father. “Some Infallible Characteristics of Christ” is the creation of published author, Rev. ... a Baptist Church for thirteen years, a preacher for over nineteen, a pastor for ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 23, 2017 LifeVac, the revolutionary device that ... and prevented choking deaths, welcomes Steve Way , ... LifeVac team as Official Spokesperson. "We ... team," said Arthur Lih , Founder and CEO ... and his mission to raise awareness about the physically ...
(Date:1/23/2017)... Jan 23, 2017 Research and Markets has announced ... Trends - Product - Forecast to 2025" report to their offering. ... Report Highlights: ... market trends to identify the investment opportunities Market forecasts ... Key market trends across the business segments, Regions and Countries ...
(Date:1/23/2017)... -- Stock-Callers.com today presents the following Generic Drugs ... ), Sophiris Bio Inc. (NASDAQ: SPHS ), Momenta ... Inc. (NASDAQ: AGRX ). These companies are part ... trade on Friday, January 20 th , 2017, with the ... health care companies in the S&P 500 also were sinking ...
Breaking Medicine Technology: